Britain and America have concluded a landmark bilateral deal that will preserve zero tariffs on UK drug products entering the American market.
Key Provisions of the Pact
As part of the deal, the UK has agreed to raise spending on pharmaceuticals through the NHS. This commitment secures that duties on these key exports will be held at zero for a duration of 36 months.
This agreement comes after recent statements to hike import taxes on branded drug imports, with figures floated up to one hundred percent.
"This deal between the Britain reinforces the international landscape for new treatments and introduces much-needed equity to transatlantic pharmaceutical trade," a statement noted.
Trade Importance
Drugs represent one of the the United Kingdom's biggest exports to the US, which is by far the primary destination for leading companies like GSK and AstraZeneca.
Trade data show that in the one-year period leading up to the third quarter, the UK shipped drugs valued at £11.1bn to the US. This amount represented 17.4% of all goods exports in that period.
"This guarantee safeguards employment, stimulates capital expenditure and paves the way for the UK to become a worldwide center for medical research," the Business and Trade Secretary stated.
Key British Pledges
The pact includes several key commitments from the United Kingdom:
- Revised Affordability Limit: The UK will lift the price threshold at which it considers new therapies to be too expensive by twenty-five percent.
- Increased NHS Spending: There is a goal to increase overall public funding on drugs from 0.3 percent of the national economy to 0.6 percent over the coming ten years.
- Rebate Cap: The sum drug companies must return to the NHS to control costs will be capped at 15%. Last year, refunds exceeded 20%.
Recent Tensions
The deal comes amid a long-running dispute between the pharmaceutical industry and the ministers over spending levels and regulatory access.
The disagreement were heightened by claims that American patients were paying a premium for the identical medicines than patients in the other developed nations.
Recently, several large drug company projects in the UK have been halted or scrapped, while major expansions have been announced toward American operations.
One official acknowledged that the NHS needed to increase expenditure on treatments, noting that its expenditure on drugs had declined as a percentage of its overall budget over the past decade.
